bluebird bio Inc.

4.40+0.1200+2.80%Vol 7.66M1Y Perf -86.76%
Jun 24th, 2022 16:00 DELAYED
BID4.11 ASK4.18
Open4.25 Previous Close4.28
Pre-Market- After-Market4.34
 - -  -0.06 -1.36%
Target Price
12.89 
Analyst Rating
Hold 3.24
Potential %
192.96 
Finscreener Ranking
★+     43.41
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     50.42
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     45.05
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
5.08 
Earnings Rating
Buy
Market Cap314.39M 
Earnings Date
8th Aug 2022
Alpha-0.05 Standard Deviation0.17
Beta1.69 

Today's Price Range

4.024.49

52W Range

2.8733.09

5 Year PE Ratio Range

-7.30-3.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
23.60%
1 Month
46.67%
3 Months
-11.65%
6 Months
-61.40%
1 Year
-86.76%
3 Years
-96.33%
5 Years
-96.07%
10 Years
-

TickerPriceChg.Chg.%
BLUE4.400.12002.80
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.60
1.80
0.24
0.42
-
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
-1 218.40
-11 444.10
-11 119.40
-2 442.70
-
RevenueValueIndustryS&P 500US Markets
-7 187 000.00
-0.10
-46.11
-0.13
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.26-1.66-31.75
Q04 2021-1.82-1.820.00
Q03 2021-2.72-2.93-7.72
Q02 2021-3.26-3.58-9.82
Q01 2021-3.05-3.07-0.66
Q04 2020-3.02-3.010.33
Q03 2020-3.07-2.944.23
Q02 2020-1.91-0.3681.15
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.288.57Positive
9/2022 QR-1.1419.15Positive
12/2022 FY-4.977.79Positive
12/2023 FY-2.9231.13Positive
Next Report Date8th Aug 2022
Estimated EPS Next Report-1.28
Estimates Count7
EPS Growth Next 5 Years %38.20
Volume Overview
Volume7.66M
Shares Outstanding71.45K
Shares Float50.58M
Trades Count31.60K
Dollar Volume32.83M
Avg. Volume15.40M
Avg. Weekly Volume27.40M
Avg. Monthly Volume13.27M
Avg. Quarterly Volume5.54M

bluebird bio Inc. (NASDAQ: BLUE) stock closed at 4.4 per share at the end of the most recent trading day (a 2.8% change compared to the prior day closing price) with a volume of 7.66M shares and market capitalization of 314.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1213 people. bluebird bio Inc. CEO is Nick Leschly.

The one-year performance of bluebird bio Inc. stock is -86.76%, while year-to-date (YTD) performance is -55.96%. BLUE stock has a five-year performance of -96.07%. Its 52-week range is between 2.865 and 33.09, which gives BLUE stock a 52-week price range ratio of 5.08%

bluebird bio Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 1.01, a price-to-sale (PS) ratio of -42.45, a price to cashflow ratio of 5.70, a PEG ratio of 2.32, a ROA of -72.23%, a ROC of -82.72% and a ROE of -105.35%. The company’s profit margin is -%, its EBITDA margin is -11 119.40%, and its revenue ttm is $-7 187 000.00 , which makes it $-0.10 revenue per share.

Of the last four earnings reports from bluebird bio Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.28 for the next earnings report. bluebird bio Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for bluebird bio Inc. is Hold (3.24), with a target price of $12.89, which is +192.96% compared to the current price. The earnings rating for bluebird bio Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

bluebird bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

bluebird bio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.28, ATR14 : 0.59, CCI20 : 110.92, Chaikin Money Flow : -0.29, MACD : 0.16, Money Flow Index : 79.50, ROC : 39.24, RSI : 59.25, STOCH (14,3) : 46.48, STOCH RSI : 0.92, UO : 53.18, Williams %R : -53.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of bluebird bio Inc. in the last 12-months were: Andrew Obenshain (Sold 8 557 shares of value $82 093 ), Douglas G. Cole (Sold 9 942 shares of value $95 105 ), Jessica Whitten (Sold 3 393 shares of value $35 056 ), Nick Leschly (Sold 7 437 shares of value $71 143 ), Thomas J. Klima (Sold 3 753 shares of value $11 535 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (7.14 %)
1 (7.69 %)
2 (15.38 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
10 (71.43 %)
10 (76.92 %)
9 (69.23 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
3 (21.43 %)
2 (15.38 %)
2 (15.38 %)
Summary RatingHold
3.24
Hold
3.10
Hold
2.95

bluebird bio Inc.

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

CEO: Nick Leschly

Telephone: +1 339 499-9300

Address: 60 Binney Street, Cambridge 02142, MA, US

Number of employees: 1 213

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

76%24%

Bearish Bullish

66%34%

TipRanks News for BLUE

Wed, 06 Apr 2022 14:55 GMT Bluebird Bio (BLUE) Gets a Hold Rating from William Blair

- TipRanks. All rights reserved.

Wed, 06 Apr 2022 12:40 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Bluebird Bio (BLUE) and Merck & Company (MRK)

- TipRanks. All rights reserved.

Tue, 08 Mar 2022 12:31 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Brickell Biotech (BBI), Bluebird Bio (BLUE) and Aurinia Pharmaceuticals (AUPH)

- TipRanks. All rights reserved.

Tue, 08 Mar 2022 06:32 GMT Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Bluebird Bio (BLUE) and Oncolytics Biotech (ONCY)

- TipRanks. All rights reserved.

Mon, 07 Mar 2022 16:45 GMT Bluebird Bio (BLUE) Receives a Sell from Morgan Stanley

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 18:43 GMT bluebird bio May Need to Raise Cash Soon

- TipRanks. All rights reserved.

News

Stocktwits